The US is the bigger Alzheimers Dignostic market: $882 Mn against $169 Mn in 2023, about 5.2 times as large.
China grows faster: 8.4% a year, against 4.9%. The gap still grows from $713 Mn to $1 Bn by 2033.
Clinical research: 429 active trials in the US, 148 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $882 Mn | $169 Mn |
| Market size, 2033 projected | $1.4 Bn | $378 Mn |
| Growth a year (CAGR) | 4.9% | 8.4% |
| Money added, 2023–2033 | $541 Mn | $209 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $2.58 | $0.12 |
| Active clinical trials | 429 | 148 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Alzheimers Dignostic, US or China?
The US is the bigger Alzheimers Dignostic market: $882 Mn against $169 Mn in 2023, about 5.2 times as large.
Which grows faster in Alzheimers Dignostic, US or China?
China grows faster: 8.4% a year, against 4.9%. The gap still grows from $713 Mn to $1 Bn by 2033.
More Alzheimers Dignostic comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.